Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
2008
Dasatinib's Effects on EphA2 in Pancreatic Cancer
publication
Evidence: moderate
Author Information
Author(s): Chang Q, Jorgensen C, Pawson T, Hedley D W
Primary Institution: Ontario Cancer Institute/Princess Margaret Hospital
Hypothesis
Inhibition of EphA2 by dasatinib.
Conclusion
Dasatinib inhibits EphA2 receptor activity, suggesting potential therapeutic benefits in pancreatic cancer.
Supporting Evidence
- Dasatinib directly inhibits EphA2 receptor activity in pancreatic cancer cell lines.
- Treatment with dasatinib decreased EphA2 phosphorylation in xenograft models.
- EphA2 is overexpressed in pancreatic cancer, making it a potential therapeutic target.
Takeaway
Dasatinib is a medicine that can help stop a protein called EphA2 from working too much in pancreatic cancer, which might help treat the disease.
Methodology
In vitro kinase assays and xenograft models were used to assess the effects of dasatinib on EphA2 activity.
Limitations
The study primarily focused on in vitro and xenograft models, which may not fully represent human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website